Bryan T J Hennessy

Summary

Publications

  1. pmc Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer
    M S N Mohd Sharial
    Department of Medical Oncology, Beaumont Hospital, Dublin, Ireland
    Ann Oncol 23:3007-16. 2012
  2. pmc An efficient procedure for protein extraction from formalin-fixed, paraffin-embedded tissues for reverse phase protein arrays
    Huifang Guo
    Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Proteome Sci 10:56. 2012
  3. pmc Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer
    Ana M Gonzalez-Angulo
    Departments of Breast Medical Oncology and Systems Biology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Clin Proteomics 8:11. 2011
  4. pmc Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer
    Chad J Creighton
    Dan L Duncan Cancer Center, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    Breast Cancer Res 12:R40. 2010
  5. pmc Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer
    Bryan T J Hennessy
    Department of Gynecology Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 28:3570-6. 2010
  6. pmc c-Jun-NH2-kinase-1 inhibition leads to antitumor activity in ovarian cancer
    Pablo Vivas-Mejia
    Department of Experimental Therapeutics, Center for RNAi and non coding RNA, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 16:184-94. 2010

Collaborators

  • L Rubin
  • Mark S Carey
  • Jie Li
  • Yang Li
  • Maurie Markman
  • Ariel Fernandez
  • Karen H Lu
  • Gordon B Mills
  • Huifang Guo
  • M S N Mohd Sharial
  • Wenbin Liu
  • Zhenlin Ju
  • Ana M Gonzalez-Angulo
  • Ana Lluch
  • Chad J Creighton
  • Pablo Vivas-Mejia
  • Dimitra Tsavachidou
  • J Crown
  • Pheroze Tamboli
  • Yiling Lu
  • Eric Jonasch
  • Lajos Pusztai
  • Anne Lise Borresen-Dale
  • Powel Brown
  • Gabriel N Hortobagyi
  • Lei Deng
  • Sam Aparicio
  • Corey Speers
  • Jens Overgaard
  • Jan Alsner
  • W Fraser Symmans
  • Simen Myhre
  • Kevin R Coombes
  • Funda Meric-Bernstam
  • Russell Broaddus
  • Aysegul Sahin
  • Alpa M Nick
  • Yvonne G Lin
  • Zhengong Peng
  • Hee Dong Han
  • Hye Sun Kim
  • Angela Sanguino
  • Ana Maria Gonzalez-Angulo
  • Juliana Maria Benito
  • Yiqun Zhang
  • Francois Xavier Claret
  • Cristian Rodriguez-Aguayo
  • Rebecca L Stone
  • Angelo J Casa
  • Powell H Brown
  • Rachel Schiff
  • William Bornmann
  • Gabriel Lopez-Berestein
  • Susan G Hilsenbeck
  • Joe W Gray
  • Arturo Chavez-Reyes
  • Xiaoyong Fu
  • C Kent Osborne
  • Adrian V Lee
  • Anil K Sood
  • Lingegowda Mangala

Detail Information

Publications6

  1. pmc Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer
    M S N Mohd Sharial
    Department of Medical Oncology, Beaumont Hospital, Dublin, Ireland
    Ann Oncol 23:3007-16. 2012
    ..HER2-targeted therapy has substantially improved outcomes in patients with HER2-positive breast cancer. However, both de novo and acquired resistance are observed...
  2. pmc An efficient procedure for protein extraction from formalin-fixed, paraffin-embedded tissues for reverse phase protein arrays
    Huifang Guo
    Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Proteome Sci 10:56. 2012
    ..abstract:..
  3. pmc Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer
    Ana M Gonzalez-Angulo
    Departments of Breast Medical Oncology and Systems Biology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Clin Proteomics 8:11. 2011
    ..abstract:..
  4. pmc Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer
    Chad J Creighton
    Dan L Duncan Cancer Center, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    Breast Cancer Res 12:R40. 2010
    ..We thus examined whether deregulated PI3K signaling in luminal ER+ breast tumors is associated with ER level and activity and intrinsic molecular subtype...
  5. pmc Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer
    Bryan T J Hennessy
    Department of Gynecology Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 28:3570-6. 2010
    ..3%. It is important to determine the frequency of somatic BRCA(1/2) changes, given the sensitivity of BRCA-mutated cancers to poly (ADP ribose) polymerase-1 (PARP1) inhibitors and platinum analogs...
  6. pmc c-Jun-NH2-kinase-1 inhibition leads to antitumor activity in ovarian cancer
    Pablo Vivas-Mejia
    Department of Experimental Therapeutics, Center for RNAi and non coding RNA, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 16:184-94. 2010
    ..To show the functional, clinical, and biological significance of c-Jun-NH(2)-kinase (JNK)-1 in ovarian carcinoma...